Entrada Therapeutics (TRDA) Cash & Equivalents (2020 - 2026)

Entrada Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $76.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 12.69% year-over-year to $76.4 million; the trailing twelve-month figure through Mar 2026 stood at $76.4 million (up 12.69% YoY), and the FY2025 full-year result was $90.4 million, down 10.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $76.4 million, down from $90.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $227.6 million in Q1 2023, with the low at $45.2 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $90.2 million, with a median of $78.0 million recorded in 2024.
• Year-over-year, Cash & Equivalents sank 84.49% in 2022 and surged 168.96% in 2023.
• Tracing TRDA's Cash & Equivalents over 5 years: stood at $45.2 million in 2022, then soared by 49.7% to $67.6 million in 2023, then soared by 49.72% to $101.2 million in 2024, then decreased by 10.69% to $90.4 million in 2025, then retreated by 15.43% to $76.4 million in 2026.
• The last three Cash & Equivalents figures came in at $76.4 million (Q1 2026), $90.4 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.

Peer Comparison